Generic Name and Formulations:
Oxaprozin 600mg; scored caplets.
Indications for DAYPRO:
Rheumatoid arthritis (RA). Osteoarthritis (OA). Juvenile rheumatoid arthritis (JRA).
Use lowest effective dose for shortest duration. RA (≥16yrs) or OA: 1.2g once daily; max 1.8g or 26mg/kg daily, whichever is less, in divided doses. Low body weight, severe renal impairment, or on dialysis: initially 600mg once daily; max 1.2g daily.
Use lowest effective dose for shortest duration. <6yrs: not established. JRA: 6–16yrs (22–31kg): 600mg once daily; (32–54kg): 900mg once daily; (≥55kg): 1.2g once daily.
Aspirin allergy. Coronary artery bypass graft surgery.
Increased risk of serious cardiovascular events (including MI, stroke). Avoid in recent MI, severe heart failure; if necessary, monitor. Increased risk of serious GI adverse events (including inflammation, bleeding, ulceration, perforation). History of ulcer disease and/or GI bleeding. Hypertension; monitor BP closely. Hepatic or renal impairment. Discontinue if signs/symptoms of liver disease develop, or if abnormal LFTs persist or worsen. Dehydration. Hypovolemia. Advanced renal disease: not recommended. Hyperkalemia. Coagulation disorders. Monitor CBCs, blood chemistry, hepatic, and renal function in long-term therapy. Pre-existing asthma. May mask signs of infection or fever. Discontinue at 1st sign of rash or any other hypersensitivity. Elderly. Debilitated. Labor & delivery. Pregnancy (≥30 weeks gestation; avoid). Nursing mothers.
Avoid concomitant aspirin, salicylates (eg, diflunisal, salsalate) or other NSAIDs. Increased risk of GI bleed with anticoagulants, antiplatelets, oral corticosteroids, SSRIs, SNRIs, smoking, alcohol, or prolonged NSAID therapy; monitor. May antagonize, or increase risk of renal failure with diuretics (eg, loop or thiazides), ACE inhibitors, ARBs, or β-blockers; monitor closely. Potentiates digoxin; monitor levels. May potentiate lithium, methotrexate, cyclosporine; monitor for toxicity. Concomitant with pemetrexed may increase risk of pemetrexed-associated myelosuppression, renal, and GI toxicity. Concomitant glyburide: monitor blood glucose at initiation. May cause false (+) results of benzodiazepine urine screening tests.
NSAID (propionic acid deriv.).
Constipation, diarrhea, dyspepsia, nausea, rash (may be serious), edema, anemia, CNS effects, tinnitus, dysuria; cardiovascular thrombotic events, GI ulcer/bleed, hepatotoxicity, renal toxicity, hypersensitivity reactions, photosensitivity.